Media coverage about Nuvectra (NASDAQ:NVTR) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nuvectra earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.2313320226724 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Nuvectra (NASDAQ NVTR) opened at $7.76 on Friday. The firm has a market cap of $83.90, a P/E ratio of -1.65 and a beta of -0.91. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.72 and a current ratio of 2.90. Nuvectra has a 12-month low of $4.90 and a 12-month high of $15.00.
Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.07. The firm had revenue of $7.60 million for the quarter, compared to analysts’ expectations of $8.08 million. Nuvectra had a negative net margin of 204.19% and a negative return on equity of 68.63%. Nuvectra’s revenue was up 100.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.92) earnings per share. equities research analysts predict that Nuvectra will post -4.58 EPS for the current year.
Nuvectra Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.